Auna vs Starling Oncology
AUNA and STLN side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AUNA and STLN compare
Starling Oncology grew revenue faster over the last twelve months (38.4% versus −0.02% for Auna).
Auna keeps more of each dollar of sales as profit, with a net margin of 2.2% compared with −6.2% at Starling Oncology.
Starling Oncology scores higher on the StockData Score (6 against 5 for Auna), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AUNA | STLN |
|---|---|---|
| Size and price | ||
| Market cap | – | $666M |
| Share price | $4.51 | $6.53 |
| Change, 1 year | −23.8% | 38.9% |
| Change, 5 years | – | −34.6% |
| Beta (5Y) | 0.64 | 1.60 |
| Employees | 15K | 641 |
| StockData Score | ||
| Total score | 5 | 6 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 1 | 2 (better) |
| Performance score | 3 (better) | 2 |
| Health score | 1 | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 1.1× |
| FCF yield | – | −0.49% |
| Growth | ||
| Revenue growth (TTM) | −0.02% | 38.4% (better) |
| Revenue growth, 5Y average | – | 21.8% |
| Net income growth (TTM) | −11.5% | – |
| EPS growth (TTM) | −19.0% | – |
| Profitability | ||
| Gross margin | 37.9% | – |
| Operating margin | 14.3% (better) | −4.4% |
| Net margin | 2.2% (better) | −6.2% |
| FCF margin | 13.1% (better) | −0.56% |
| Return on equity | 6.3% | – |
| Return on invested capital | 7.2% (better) | −83.1% |
| Financial health | ||
| Debt / equity | 2.21 | – |
| Net debt / EBITDA | 3.77 | – |
| Interest coverage | 1.0× (better) | −3.4× |
| Current ratio | 1.11 | 1.36 (better) |
| Altman Z-score | – | 2.78 |
| Piotroski F-score | 5 (better) | 3 |
| Dividends and buybacks | ||
| Shareholder yield | – | 0.00% |
| Ownership | ||
| Held by institutions | 8.1% | 43.4% |
| Held by insiders | 49.1% | 56.6% |
| Insider net buying, 12 months | $284K (better) | −$122K |
Go deeper
- AUNA stock overview
- AUNA income statement
- AUNA valuation and score
- STLN stock overview
- STLN income statement
- STLN valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.